- Oh, D. Y., Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., van Cutsem, E., Molena, D., . . . Tabernero, J. (2023). Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annals of Oncology, 34, S1520-S1521. https://doi.org/10.1016/j.annonc.2023.10.265
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
on 11 de març de 2024
with No hi ha comentaris
Deixa un comentari